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Abstract
Background: Multiple sclerosis (MS) is a central nervous system disease associated with irreversible progression of
disability, which imposes a substantial socioeconomic onus. The objective of this study was to determine the
economic impact of multiple sclerosis from the Brazilian household and healthcare system perspectives. Secondary
objectives were to assess the impact of fatigue on daily living and health-related quality of life (HRQL) of MS
patients.
Methods: This is a cross-sectional study in which Brazilian eligible patients attending eight major MS specialized
sites answered an interview capturing data on demographics, disease characteristics and severity, comorbidities,
resource utilization, fatigue, utilities and health-related quality of life from November/2011 to May/2012 . Costs were
assessed considering a prevalence-based approach within 1 year of resource consumption and were estimated by
multiplying the amount used by the corresponding unit cost. Patients were classified as having mild, moderate or
severe disability according to the Expanded Disability Status Scale (EDSS).
Results: In total, 210 patients who met eligibility criteria were included, 40 % had mild, 43 % moderate and 16 %
severe disability; disability level was missing for 1 %. The average total direct cost per year was USD 19,012.32
(SD = 10,465.96), and no statistically significant differences were not observed according to MS disability level
(p = 0.398). The use of disease modifying therapies (DMTs) corresponded to the majority of direct expenditures,
especially among those patients with lower levels of disability, representing around 90 % of total costs for mild
and moderate MS patients. It was also observed that expenses with medical (except DMTs) and non-medical
resources are higher among patients with more severe disease. Worsening disability also had an important
influence on health-related quality of life and self-perceived impact of fatigue on daily living.
Conclusion: Our data demonstrates the significant economic impact of MS on both Brazilian household and
health system, in terms of DMTs and other disease management costs. When patients move upwards on the
disease severity scale, costs with health resources other than drugs are significantly increased.
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Background
Multiple sclerosis (MS) is an inflammatory and demye-
linating disease of the central nervous system that can
cause several symptoms that include upper and lower
extremity disabilities, visual disturbances, balance and
coordination problems, spasticity, altered sensation, ab-
normal speech, swallowing disorders, fatigue, bladder
and bowel problems, sexual dysfunction, and cognitive
and emotional disturbances [1–3]. It is estimated that
about 2.5 million people are living with the disease
worldwide [4] and in Brazil, MS prevalence is estimated
to range from 1.36 to 20/100,000 inhabitants, depending
on the characteristics of the studied population [4, 5].
Although people can be diagnosed at any age, MS is
usually diagnosed during early adulthood and the aver-
age age of MS onset is 30 years [4]. MS can be found in
four different forms (relapsing-remitting, primary pro-
gressive, progressive relapsing and secondary progres-
sive). The relapsing-remitting type is the most frequent
at the time of diagnosis (about 85 %) and it is estimated
that up to 80 % of these patients will evolve to the
secondary progressive form [4].
Despite its low prevalence relative to other chronic dis-
eases, such as diabetes and coronary artery diseases, MS
imposes a considerable socioeconomic onus [6, 7]. Ana-
lyses of MS costs conducted in several countries have
demonstrated that costs are largely driven by the progres-
sion of patients to severe stages of disability [8, 9]. Com-
pared to mild disability, severe disability is associated with
increased costs of hospitalizations, consultations, labora-
tory tests and other drugs, although the cost of immuno-
modulatory drugs is low [8, 9]. Indeed, direct medical
costs in the early disease stages are outweighed by indirect
costs, associated with decreased work and productivity, in
later stages [10]. Furthermore, intangible non-monetary
adverse impacts of MS, such as health-related loss of qual-
ity of life and symptoms like fatigue, represent an import-
ant concern for patients and families [11–13]. Within the
scope of economic analysis in health care, patients’ quality
of life is usually translated into a measure related to eco-
nomic theory named utility which was also previously
described for MS [3, 8, 9, 14–18].
So far, there are few studies that addressed costs asso-
ciated with MS in Brazil. All studies focused on medical
direct costs, especially those related to the use of disease
modifying therapies (DMTs), and analyses were con-
ducted from the Brazilian Unified Health System (SUS)
perspective [19–23]. In fact, DMTs are available to MS
patients in the public sector through the Specialized
Component of Pharmaceutical Assistance Program of
SUS [24–26].
In the Brazilian health system, the public (SUS) and
private sectors (Supplementary Health System and out-
of-pocket) are distinct but interconnected, and people
can use services provided by either sectors depending on
ease of access or their ability to pay [27]. Currently, SUS
is a universal system in which the government, at fed-
eral, state and city levels, provides health services funded
by taxes [27]. Besides SUS, around 25 % of Brazilians,
mostly employees from public and private companies,
are also covered by the Supplementary Health System
(SH) constituted by different private health insurance
plans [27]. SUS and SH have specific lists of coverage in-
cluding medications, exams, consultations and hospitali-
zations [28–30]. In the out-of-pocket subsector, services
are directly paid by patients within the private health
market [27].
In the current scenario of increasing healthcare costs,
with limited budget and higher demand for new tech-
nologies, cost-of-illness studies can be relevant to sup-
port policy-makers in the resource allocation process
[31, 32]. Considering this, it is important to quantify the
costs of MS to better understand the impact of the dis-
ease not only on the health system, but also on patients
and their families.
Although there are some reports describing MS-
related costs funded by the public health sector [19–23],
there is a lack of studies describing MS-related costs in-
cluding healthcare system and Brazilian household per-
spectives, i.e., considering direct costs funded by SUS,
SH and directly paid by patients and their families. Thus,
the primary aim of the study was to assess the economic
impact of MS from the Brazilian household and health-
care system perspectives. Secondary objectives were to
assess the impact of fatigue on daily living and health-
related quality of life (HRQL) of MS patients.
Methods
Study design and patient assessment
This was a multicenter, cross-sectional study conducted
in eight sites, 5 public, 1 private and 2 with mixed fund-
ing, specialized in MS treatment in Southern and South-
eastern regions of Brazil. Patients were screened for
eligibility and consecutively invited to participate, as they
attended a routine visit at study sites. If they agreed, they
were asked to sign an informed consent. Patients were
deemed eligible if they were at least 18 years old and if
they had clinical diagnosis of MS according to the re-
vised McDonald criteria [33]. Patients were excluded if
they had any physical or mental condition that would
impair their understanding and ability to answer the
study interview (particularly the self-reported measures
of HRQL and fatigue) and/or if they were already
enrolled in a clinical trial at the time of enrolment. This
study was approved by the independent Ethics Commit-
tees of each participating site. During data collection,
which occurred between November/2011 and May/2012,
patients answered a face-to-face structured interview in
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Portuguese, conducted by a clinical research assistant dur-
ing an outpatient routine visit. This interview aimed to
collect self-reported variables about socio-demographics
and clinical aspects, disability level, professional activities,
including early retirement and sick leaves, HRQL and im-
pact of fatigue on daily living (both measured using vali-
dated questionnaires as described in the sessions below)
and health resource utilization.
Disability Level
The Expanded Disability Status Scale (EDSS) was used
to assess patients’ disability level. It is a self-reported in-
strument composed by 20 items with scores ranging
from 0 to 10 points, increasing in accordance with the
disability level. This is a well-established method used in
clinical trials, epidemiological studies and in clinical
practice [34]. Patients were classified as having mild,
moderate or severe disability according to the following
cutoffs: 0–3 (mild), 4–6.5 (moderate), and ≥7 (severe), as
previously described by other authors [14, 35].
Health-related quality of life and utility measures
Quality of life and utility measures are different concepts
that are related to each other. Utility derives from Neu-
mann and Morgenstern’s economic theory for the deci-
sion making process, in which a model was developed to
represent how people make decisions when they face
uncertainty conditions, based on individual preferences
[36]. So, utility measures come from an individual judg-
ment of different health statuses and summarize con-
cepts related to health, well-being and quality of life.
Utility measures are usually used to define public health
policies, resource allocation and the evaluation of ser-
vices and programs, as a proxy of how people value spe-
cific changes in health status related to new therapies,
for example [36]. Measures usually range from 0 to 1,
and are conceptually valued using as a reference death
as the worst health state (equal to 0) and perfect health
as the best health state (equal to 1).
Health-related Quality of life was assessed using the
EQ-5D (EuroQol 5 Dimensions Questionnaire) which
measures generic quality of life through questions asses-
sing the level of impairment in five 5 different domains
(mobility, self-care, usual activities, pain/discomfort and
anxiety/depression) and an additional self-applicable vis-
ual analogue scale (EQ-VAS). Each domain has 3 re-
sponse levels (no problem, some problem and serious
problem) and in EQ-VAS patients graduate their general
health status from 0 (worst imaginable health state) to
100 (best imaginable health state) [37].
Data obtained from EQ-5D were subsequently con-
verted into a utility index, using the algorithm developed
for the United Kingdom, as there were no conversion
methods available for the Brazilian population at the
time of development of the study protocol [38, 39].
Impact of fatigue
The impact of fatigue on daily living of MS patients was
assessed through the MFIS-BR (Modified Fatigue Impact
Scale, Brazilian Portuguese version), which measures the
impact of fatigue through 21 questions about physical,
cognitive and psychosocial domains [40]. Impact of fa-
tigue was considered as absent when total score was ≤38
points; low when the score was between 39 and 58
points; and high when ≥59 points [40].
Productivity loss
Productivity loss was assessed through the analysis of
early retirement due to MS and the occurrence of sick
leaves for those currently working. These data were re-
ported by patients during the face-to-face structured
interview. Productivity-related variables were analyzed
only to describe the overall impact of MS for patients,
without converting them into monetary values.
Resource utilization
To assess resource utilization, patients were asked by an
interview, using a specific study questionnaire, about the
consumption of specific MS-related health resources.
Different recall periods were used for each type of re-
source: i) one month for assistance from family or
friends; ii) three months for medications and assistance
from contracted paid caregivers; iii) six months for out-
patient visits and emergency department visits; iv) twelve
months for relapses, hospitalizations, tests and major in-
vestments (home or vehicle adaptation, acquisition of
walking aids, among others.). To ensure comparability,
in a subsequent step all resources were annualized.
Costs
Costs were assessed considering a prevalence-based
approach and the time period of 1 year of resource con-
sumption. Only costs directly related to diagnosis, man-
agement and treatment of MS were estimated. To better
understand the funding of MS resources in the study,
costs were divided according to the source of funding
(the healthcare system or the patient/family), which
defines different study economic perspectives – the per-
spective of the household (costs funded by patients and
families, i.e., out-of-pocket expenses) and the perspective
of the healthcare system (costs funded by SUS or SH).
Direct costs related to MS management were estimated
by multiplying the amount of resources used by the cor-
responding unit cost. Unit costs for each resource used
(SH and/or SUS) were collected on July/2012 from the
latest available value described in the Brazilian official
price lists, in 2012 Brazilian Real values (BRL), as
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follows: Health Price Database from the Brazilian Ministry
of Health, for medication [41]; Unified Health System
Management System of the Table of Procedures, Medi-
cines, Orthotics, Prosthetics and Special Materials (SIG-
TAP), for complementary exams, hospitalizations and
consultations at SUS [42]; and Hierarchical Brazilian Clas-
sification of Medical Procedures (CBHPM) from the
Brazilian Medical Association, for consultations in the pri-
vate setting [43]. Expenses related to non-prescribed drugs
(OTC medication), equipment and other investments and
professional caregivers were reported by patients during
the interview. These data were reported considering the
source of funding, patients or healthcare system, and costs
related to disease modifying therapies (DMTs) were
reported separately, as patients with severe disability are
not always treated with DMTs which can potentially be a
confounding factor.
Costs were also analyzed according to the level of dis-
ability (EDSS), impact of fatigue (MFIS-BR cut-offs for
impact of fatigue) and other patients’ demographics and
clinical characteristics. Brazilian real values (BRL) were
converted into American dollar values (USD) using the
exchange rate of the date of consultation to the price list
(08/24/2012), where USD1.00 corresponded to BRL
2.0255.
Statistical analysis and sample size
Since a standard method for sample size calculation in
cost of illness studies is not available and this is a part of
a broad study that also assessed patients’ preferences re-
lated to MS treatment characteristics [44], sample size
was calculated in order to evaluate that outcome. It was
estimated that 210 respondents would be enough to ob-
tain measures with a significance level of 5 %. For the
HRQL outcome assessed through utility measures, the
estimated sample size (N = 210) was validated, and using
a SD = 0.32, the variability provided would be ≈ 0.08.
Shapiro-Wilk and Jarque-Bera tests were used to test for
normal distribution of data.
All data were submitted to exploratory analysis to de-
scribe measures of central tendency and dispersion for
continuous variables and frequency for categorical vari-
ables. In the univariate analysis of total costs, compari-
sons between groups were performed using the chi-
square of Pearson test (for frequencies) and ANOVA
(normal distributions) with the post hoc Bonferroni or
Kruskal-Wallis (non-normal distribution) test were used
(for means). The same tests and criteria were used to
compare means according to EDSS levels (mild, moder-
ate and severe).
In the multivariate analysis, ANOVA with partial sums
of squares (Partial SS) test was employed to analyze the
association between MS-related direct costs and the fol-
lowing variables: EDSS level, gender, educational level,
impact of fatigue level (MFIS scale), MS relapse, any
self-reported comorbidities, type of MS, and occupation.
All analyses were performed using the statistical software
Stata (version MP11) and R Project (version 2.13.1). The
95 % confidence interval and a p value ≤0.05 were
assumed for statistical significance.
Ethics approval
A written consent was obtained from all the respondents
before conducting the interviews. This study was ap-
proved by independent Ethics Committees of each par-
ticipating research site: Comitê de Ética em Pesquisa da
Universidade Metropolitana de Santos-UNIMES (no. 18/
2011); Comitê de Ética em Pesquisa da Faculdade de
Ciências Médicas da Universidade Estadual de Campinas
- UNICAMP (no. 433/164 211); Comitê de Ética em
Pesquisa da Irmandade da Santa Casa de Misericórdia
de São Paulo - ISCMSP (no. 173/11); Comitê de Ética
em Pesquisa do Hospital de Clínicas de Porto Alegre -
HCPA (no. 166 110267); Comissão de Ética para Análise
de Projetos de Pesquisa – CAPPesq da Diretoria Clínica
do Hospital das Clínicas da Faculdade de Medicina da
Universidade de São Paulo - FMUSP (no. 0571/11);
Comitê de Ética em Pesquisa da Universidade Federal de
São Paulo - UNIFESP/Hospital São Paulo (no. 0769/11);
Comitê de Ética em Pesquisa da Pontif ícia Universidade
Católica do Rio Grande do Sul - PUCRS (no. 12/05750);
Comitê de Ética em Pesquisa do Hospital Municipal São
José – Joinville/SC (no. 12004).
Results
Patients’ demographics and clinical characteristics
In total, 210 patients who met eligibility criteria were in-
cluded in the study. Most of them (70 %) were female,
with a mean age of 40.7 (SD = 11.5) years old, living with
family/spouse (94 %) and with an average monthly in-
come of USD 806.47 (SD = 869.39). Patients’ EDSS clas-
sification was: 40 % had mild disability (EDSS 0–3), 43 %
had moderate disability (EDSS 4–6.5), and 16 % had se-
vere disability (EDSS 7–9). The majority of patients had
relapsing-remitting disease (79 %) and 85 % of patients
with severe disability (EDSS 7–9) had secondary pro-
gressive disease.
Occurrence of a relapse in the previous year was
reported by 49 % of the total sample, being different
across EDSS levels (Mild: 49 %; Moderate: 57 %; Severe:
24 %). Details on patients’ demographic and clinical
characteristics are described in Table 1;a statistically sig-
nificant difference among the severity groups was ob-
served for age (p < 0.001), educational level (p = 0.044),
living (p = 0.004), MS type (p < 0.001) and at least one
episode of recurrence (p = 0.004).
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Table 1 Patients’ demographics, labor force and clinical characteristics in each EDSS level
Mild (EDSS 0–3)
(N = 84)
Moderate (EDSS 4–6.5)
(N = 91)
Severe (EDSS 7–9)
(N = 33)
TOTAL
(N = 210)a
p-values*
N (%) N (%) N (%) N (%)
Age (years) (Mean [SD]) 36.8 (10.1) 41.2 (11.4) 49.2 (10.9) 40.7 (11.5) <0.001
Gender 0.056
Male 18 (21) 30 (33) 14 (42) 62 (29)
Female 66 (79) 61 (67) 19 (58) 148 (70)
Educational level 0.044
Never been to school – – – –
Elementary schoolb 11 (13) 14 (16) 10 (30) 35 (16)
High schoolb 34 (41) 53 (58) 13 (39) 100 (48)
Higher educationb 31 (37) 21 (23) 8 (24) 61 (29)
Post-Graduationb 8 (10) 3 (3) 1 (3) 12 (6)
No information – – 1 (3) 1 (1)
Living 0.004
Alone – 8 (9) 2 (6) 11 (5)
Family/Spouse 84 (100) 83 (91) 30 (91) 198 (94)
Home support or asylum – – 1 (3) 1 (1)
Monthly income (USD$) (Mean [SD]) 817.96 (899.18) 748.93 (790.96) 904.50 (994.75) 806.47 (869.39) 0.8925
MS type <0.001
Relapse-remitting 84 (100) 75 (82) 5 (15) 166 (79)
Secondary progressive – 16 (18) 28 (85) 44 (21)
Diagnosis time (years) (Mean [SD]) 5.2 (4.4) 8.2 (5.8) n.a. 7.9 (6.2)
Comorbities 64 (76) 79 (87) 30 (91) 173 (82) 0.074
Relapses (Y/N) 41 (49) 52 (57) 8 (24) 102 (49) 0.004
Number of relapses in the last year (Mean [SD]) 1.5 (1.0) 1.7 (1.0) 1.4 (0.5) 1.6 (1.0)
Employed/Self-employed 51 (31) 17 (19) 0 (0) 70 (34) <0.001
Sick leave due to Multiple Sclerosisc 15 (29) 11 (65) n.a. 26 (37) 0.089
Sick leave duration (days) (Mean [SD]) 170.5 (258.4) 90.9 (75.0) n.a. 141.7 (198.7)
Early retirement by disease or disablement 9 (11) 48 (53) 21 (64) 78 (37) <0.001
Time between diagnosis and retirement (years)
(Mean [SD])
4.9 (5.1) 3.5 (3.9) 4.2 (4.2) 3.9 (4.1)
Age at retirement (years) (Mean [SD]) 42 (12.0) 38 (8.9) 39 (9.9) 39 (9.5)
Health-related Quality of Life (EQ-5D)
Mobility <0.001
no problem 56 (66.7) 7 (7.7) – 64 (30)
some problem 28 (33.3) 83 (91.2) 22 (66.7) 134 (64)
serious problem – 1 (1.1) 11 (33.3) 12 (6)
Self-care <0.001
no problem 77 (91.7) 51 (56.0) 4 (12.1) 133 (63)
some problem 7 (8.3) 40 (44.0) 18 (54.5) 66 (31)
serious problem – – 11 (33.3) 11 (5)
Usual activities <0.001
no problem 52 (61.9) 17 (18.7) 2 (6.1) 72 (34)
some problem 31 (36.9) 68 (74.7) 15 (45.5) 115 (55)
serious problem 1 (1.2) 6 (6.6) 16 (48.5) 23 (11)
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Health-related quality of life and impact of fatigue
Descriptive data regarding health-related quality of life, assessed
by the EQ-5D questionnaire and the impact of fatigue on daily
living, assessed by the MFIS-BR, are reported in Table 1.
Most of the patients have shown at least some limita-
tions in all domains evaluated by EQ-5D, except for self-
care, for which 65 % of patients reported having no
problems. The frequency of serious problems was higher
among patients with more severe disease for all of the
assessed domains, except for anxiety/depression
(Table 1). When assessing self-reported quality of life
through visual analogue scale (where values closer to
Table 1 Patients’ demographics, labor force and clinical characteristics in each EDSS level (Continued)
Pain/discomfort 0.001
no problem 39 (46.4) 21 (23.1) 7 (21.2) 68 (32)
some problem 43 (51.2) 57 (62.6) 26 (78.8) 126 (60)
serious problem 2 (2.4) 12 (13.2) – 15 (7)
no information – 1 (1.1) – 1 (1)
Anxiety/depression 0.148
no problem 35 (41.7) 30 (33.0) 15 (45.5) 80 (38)
some problem 42 (50.0) 45 (49.5) 17 (51.5) 106 (51)
serious problem 7 (8.3) 16 (17.6) 1 (3.0) 24 (11)
EQ-VAS (Mean [SD]) 82.5 (13.7) 65.8 (18.5) 59.1 (17.5) 71.6 (18.9) <0.001
Impact of fatigue on daily living (MFIS-BR) <0.001
Absent 56 (67) 33 (36) 11 (33) 102 (49)
Present - Low 17 (20) 34 (37) 16 (48) 67 (32)
Present - High 11 (13) 24 (26) 6 (18) 41 (19)
n.a. not applicable; EDSS Expanded Disability Status Scale; SD Standard Deviation; MS Multiple Sclerosis; Y/N Yes/No
*Pearson Chi-square test to categorical variables or ANOVA/Kruskal-Wallis test to continuous variables
aFor two patients information about EDSS level was unavailable and their data are included only in total analysis
bComplete/incomplete
cAmong those that reported to be currently working (EDSS 0–3, N = 51; EDSS 4–6.5, N = 17; EDSS 7–9, N = 0; Total, N = 70)
Fig. 1 Utility by MS desability level
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100 represent better state of health), the average EQ-
VAS score was 71.6 (SD = 18.9) and higher scores were
observed for patients with less severe disease (p < 0.001)
(Table 1). Utility score decreased as disability
level increased (p < 0.001), as represented in Fig. 1. The
impact of fatigue was considered absent, low and high in
49, 32 and 19 % of patients, respectively, showing that 51 %
of the total sample perceived some degree of adverse
impact of fatigue on daily living activities. A statistically sig-
nificant difference in the distribution by category was
observed in accordance to EDSS level (p < 0.001; Table 1).
Any impact (both low and high summed) was reported by
33, 63, and 66 % of patients with mild, moderate and severe
disability, respectively (Table 1). However, the same pattern
was not observed among analyzed groups when MFIS was
described as a mean score stratified by EDSS level (Fig. 2).
The mean MFIS total score for mild, moderate and se-
vere patients was 29.3, 45.0, and 45.4 (38.6 in the total sam-
ple). The mean impact scores for each domain in the total
sample were 20.0 (physical, range 0–36), 14.7 (cognitive,
range 0–40), and 3.9 (psychosocial, range 0–8), meaning
that fatigue has a proportionally higher impact in the phys-
ical than the cognitive or psychosocial domains (Fig. 2).
Productivity loss
On working status, 34 % of patients reported being cur-
rently employed. Sick leave was required by 37 % of
those who were currently working, with an annual mean
duration of 141.7 days (SD = 198.7). Furthermore, 37 %
of the sample had retired earlier due to MS, after a mean
of 3.9 years from diagnosis (SD = 4.1). Among those, the
average age of retirement was 39 years old (SD = 9.5).
Employment rate was 31, 19 and 0 % in the mild,
moderate and severe disability groups, respectively, dem-
onstrating a statistically significant difference (p < 0.001).
The frequency of early retirement due to MS was also
increased by disability severity (mild = 11 %, moderate =
53 %, and severe = 64 %; p < 0.001). Time from diagnosis
to retirement and age of retirement were not markedly
different across severity groups as shown in Table 1.
Resource utilization
Among all patients, 26 % required hospitalization, with a
mean duration of 9.02 days (SD = 9.09), and 23 % had
visited an emergency department at least once in previous
12 months. Regarding outpatient visits, 98 % attended a
neurologist appointment, 36 % a physical therapist, 22 % a
nurse, 15 % a psychologist, 11 % a general practitioner,
3 % an occupational therapist, and 36 % reported appoint-
ments with other medical specialists in previous
12 months. When asked about tests, 63 % were submitted
to magnetic resonance imaging, 12 % to lumbar puncture
and 6 % to computerized tomography.
Ninety eight percent of the total sample had been pre-
scribed disease modifying therapies and 23 % had used
over-the-counter drugs. In terms of prescribed co-
medications, 42 % used antidepressants, 16 % used pain
relief medications, 16 % used drugs for spasticity, 11 %
used drugs for insomnia, 10 % used steroids because of a
recurrence, 9 % used drugs for urologic disorders, 8 %
used anti-fatigue medications and immunotherapy and
2 % used medications related to cognition issues.
Considering utensils bought and other investments
done, 17 % reported home modifications, 17 % acquired
a walking stick, 12 % a manual wheelchair, 5 % reported
car modifications and 1 % bought an electric wheelchair.
Data regarding resource utilization, stratified among
EDSS levels, are described in Table 2.
Costs
Average total direct costs per year were USD 19,012.32
(SD = 10,465.96) per patient. No statistically significant
difference was observed according to MS disability level
(p = 0.398), as described in Table 3.
Costs for each MS disability level were also stratified
in three different categories: A, direct medical costs
Fig. 2 Mean MFIS total score by MS disability level
da Silva et al. BMC Health Services Research  (2016) 16:102 Page 7 of 12
funded by the health system, excluding DMTs; B, DMTs
funded by the health system; and, C, direct medical and
non-medical costs funded by patients (Table 3). DMTs rep-
resented around 90 % of total costs for mild and moderate
MS patients. For severe patients, DMTs represented 54 %
of total costs, followed by direct medical and non-medical
costs funded by patients (27 %) and direct medical costs
(except DMTs) funded by the health system (19 %).
In the multivariate analysis, ANOVA with partial sum
of squares was employed and only EDSS level was
Table 2 Resource utilization per patient per year in each EDSS level
Mild (EDSS 0–3) Moderate (EDSS 4–6.5) Severe (EDSS 7–9) TOTAL
(N = 84) (N = 91) (N = 33) (N = 210)a
Users (%) Mean (SD) Users (%) Mean (SD) Users (%) Mean (SD) Users (%) Mean (SD)
Inpatient care (days) 23 % 7.53 (8.57) 33 % 10.41 (10.02) 15 % 7.40 (5.41) 26 % 9.02 (9.09)
Emergency service (visits) 20 % 4.00 (1.22) 29 % 4.77 (3.88) 15 % 2.80 (0.55) 23 % 4.29 (2.94)
Outpatient visits
General Practitioner 8 % 3.14 (1.57) 13 % 2.83 (1.03) 15 % 2.40 (0.89) 11 % 2.83 (1.17)
Neurologist 96 % 5.09 (3.19) 100 % 5.19 (3.43) 97 % 3.75 (1.74) 98 % 4.94 (3.18)
Other specialist 32 % 7.26 (10.94) 36 % 4.12 (3.94) 45 % 15.47 (27.05) 36 % 7.52 (14.32)
Nurse 20 % 10.35 (13.40) 25 % 8.43 (6.32) 18 % 4.67 (1.63) 22 % 8.65 (9.32)
Physiotherapist 11 % 43.56 (19.33) 38 % 71.26 (45.64) 64 % 74.76 (46.40) 31 % 68.55 (43.94)
Psychologist 14 % 16.67 (19.97) 19 % 13.76 (17.87) 9 % 28.00 (45.03) 15 % 16.19 (21.31)
Occupational therapist 2 % 29.00 (26.87) 1 % 48.00 (n.a.) 9 % 42.67 (33.31) 3 % 39.00 (25.54)
Complementary tests
MRI 60 % 1.55 (1.00) 68 % 1.56 (1.35) 55 % 1.17 (0.51) 63 % 1.50 (1.13)
CT 7 % 1.83 (1.17) 5 % 1.40 (0.89) 3 % 1.00 (n.a.) 6 % 1.58 (1.00)
Lumbar puncture 15 % 1.15 (0.38) 11 % 1.30 (0.67) 6 % 1.00 (0.00) 12 % 1.20 (0.50)
Treatment with DMTsb 89 % n.a. 93 % n.a. 61 % n.a. 87 % n.a.
Prescribed co-medication (days)
Depression 32 % 355.56 (23.09) 46 % 324.29 (89.89) 55 % 360.00 (0.00) 42 % 341.79 (64.79)
Immunotherapy 1 % 12.00 (n.a.) 7 % 214.00 (162.85) 27 % 170.67 (114.75) 8 % 177.00 (135.09)
Anti-spasticity medication 5 % 280.00 (160.00) 15 % 360.00 (0.00) 48 % 349.50 (42.00) 16 % 345.65 (61.20)
Urologic 2 % 280.00 (138.56) 8 % 285.71 (127.39) 30 % 264.40 (157.25) 9 % 274.20 (137.71)
Pain 11 % 282.22 (154.34) 24 % 295.82 (124.29) 9 % 360.00 (0.00) 16 % 297.88 (126.59)
Steroids 13 % 28.36 (26.43) 10 % 32.44 (34.14) 3 % 8.00 (n.a.) 10 % 29.14 (29.04)
Insomnia 10 % 360.00 (0.00) 11 % 325.20 (110.05) 15 % 360.00 (0.00) 11 % 332.17 (94.39)
Fatigue 2 % 214.00 (206.47) 12 % 345.45 (48.24) 9 % 360.00 (0.00) 8 % 331.75 (80.87)
Cognition 0 % n.a. 3 % 320.00 (69.28) 3 % 360.00 (n.a.) 2 % 330.00 (60.00)
Others 25 % 296.00 (122.74) 43 % 329.95 (91.30) 30 % 360.00 (0.00) 33 % 324.06 (96.97)
OTC medication 20 % n.a. 29 % n.a. 15 % n.a. 23 % n.a.
Utensils and/or modifications
Home modifications 4 % n.a. 19 % n.a. 45 % n.a. 17 % n.a.
Car modifications 4 % n.a. 3 % n.a. 15 % n.a. 5 % n.a.
Walking stick 1 % n.a. 35 % n.a. 6 % n.a. 17 % n.a.
Wheelchair (manual) 0 % n.a. 9 % n.a. 52 % n.a. 12 % n.a.
Wheelchair (electric) 0 % n.a. 1 % n.a. 6 % n.a. 1 % n.a.
Professional care 13 % n.a. 27 % n.a. 33 % n.a. 23 % n.a.
n.a. not applicable; DMTs Disease modifying therapies; MRI Magnetic resonance imaging; CT computed tomography; EDSS Expanded Disability Status Scale; OTC
Over the counter; SD Standard Deviation
aTwo patients who presented no information for EDSS level are represented only on total. All analyses were made considering the total sample or total sample in
each group
bDMTs: Interferon beta-1a, Interferon beta-1b, Glatiramer acetate and Natalizumab
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Table 3 Mean annual cost (USD) of multiple sclerosis according to disability level
Mild
(EDSS 0–3)
Moderate
(EDSS 4–6.5)
Severe
(EDSS 7–9)
Totala P
value*
(n = 84) (n = 91) (n = 33) (n = 210)
A - Resources funded by the health system, except drugs for treating MS
Inpatient care
Mean 42.44 82.74 27.95 57.82 0.025
SD 127.05 185.01 82.40 150.78
Emergency service
Mean 4.98 8.39 2.61 6.04 0.297
SD 11.95 28.49 6.71 20.45
Consultations (visits to physicians and other healthcare professionals)
Mean 211.84 530.43 1038.29 478.08 0.001
SD 423.80 897.53 1225.55 853.99
Complementary exams
Mean 126.96 145.63 86.10 128.69 0.019
SD 149.03 179.08 96.32 156.41
Adjuvant drugs
Mean 84.56 173.98 2527.71 506.48 0.040
SD 194.46 368.22 12,174.82 4851.34
Total A
Mean 470.80 941.17 3682.67 1177.10 <0.001
SD 578.59 1166.34 12,327.31 5020.98
B - Drugs for treating Multiple Sclerosis – DMTsb
Mean 17,283.59 17,409.30 10,545.01 16,257.60 <0.001
SD 8118.31 6760.00 8853.87 7982.50
C - Resources funded by the patient
Non-prescribed drugs (OTC medication)
Mean 45.84 75.04 93,29 65.51 0.754
SD 136.62 226.18 303,62 209.56
Investment and equipment
Mean 416.71 451.84 2949.64 826.23 0.912
SD 2087.26 2148.73 7343.50 3580.73
Professional caregiver
Mean 258.14 493.48 2274.97 685.88 0.036
SD 947.76 1190.69 5279.98 2395.80
Total C
Mean 720.68 1020.37 5317.90 1577.62 0.010
SD 2339.49 2520.58 9670.85 4678.00
Total cost
Mean 18,475.08 19,370.84 19,545.57 19,012.32 0.398
SD 8256.02 7509.87 19,445.75 10,465.96
MS Multiple Sclerosis; DMTs Disease modifying therapies; EDSS Expanded Disability Status Scale; OTC over the counter; SD standard deviation
*Significant at 0.05 Kruskal-Wallis/ANOVA tests; Values in bold represent the total cost of each category (A, B and C)
aTwo patients who presented no information for EDSS level are represented only on total. All analyses were made considering the total sample or total sample in
each group
bDMTs: Interferon beta-1a, Interferon beta-1b, Glatiramer acetate and Natalizumab
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associated with higher non-DMTs direct costs (p = 0.012).
Other variables in the model were gender (p = 0.210), edu-
cation (p = 0.134), impact of fatigue (p = 0.83), episode of
recurrence (p = 0.075), having any comorbidity (p = 0.713),
MS type (p = 0.227) and current activity (p = 0.591), which
were not associated with non-DMTs direct costs.
Discussion
The primary aim of this study was to assess the eco-
nomic impact of MS from the Brazilian household and
healthcare system perspectives. Secondary objectives
were to assess the impact of fatigue on daily living and
HRQL of MS patients.
The study was designed to generate Brazilian data
about MS impact; however, it enrolled patients from
South and Southeastern regions, which have potential
differences from other regions in terms of socio-
demographic characteristics and access to specialized
MS healthcare services. Despite these differences, preva-
lence reported for the Southeast region is higher than
those reported for the Northeast and Midwest regions
[5], making data representative from the vast majority of
Brazilian MS patients. Moreover, the study also demon-
strated the impact of MS on health-related quality of life
and the impact of fatigue on daily living, providing a
broader analysis of the economic and psychosocial im-
pact of MS on patients and their families than other pre-
viously published Brazilian studies that addressed
particular aspects of the disease [19–23].
Findings indicated an average total direct cost per year
of USD 19,012.53 (SD = 10,466.07) per patient. In several
countries, previous studies have demonstrated that MS
costs are substantially high [3]. Depending on the per-
spective taken and the severity of the disease, MS costs
ranged from USD 3162 to USD 77,938 per patient per
year [45]. However, cost comparison studies are not rec-
ommended due to differences in the methodological ap-
proach, such as data collection, type of resources
included, assessment of resources, patients included,
sampling process and quality of the analysis [3, 45]. In
addition, cost drivers can vary across geographies prob-
ably due to the significant differences in the availability
of services and use of resources across countries [45].
For example, differences in DMTs costs reflect differ-
ences in utilization across countries, in study popula-
tions included in analyses, and in period of data
collection (where earlier studies have low DMTs costs
because they were conducted prior to the widespread
use of disease modifying drugs) [3].
In the present study, DMTs accounted for the majority
of direct expenditures, especially among patients with
lower levels of disability, representing around 90 % of
total costs for mild and moderate MS patients and 54 %
of total costs for severe MS patients. It was also
observed that expenses with medical (except DMTs) and
non-medical resources are higher among patients with
more severe disease.
These findings corroborate results from studies con-
ducted worldwide which have shown that severe disabil-
ity is associated with increased costs of hospitalizations,
consultations, laboratory tests and other drugs, although
the cost of immunomodulatory drugs is low [8, 9]. This
fact would explain why no statistically significant differ-
ence was observed when the total cost was stratified by
MS disability level. The analysis of productivity loss has
shown that sick leave and early retirement due to MS
were common among the studied population and they
increased according to the progression of disability. In
addition, the employment rate was significantly low
(34 % of the total sample with 100 % of those with
severe disability being unemployed or retired), particu-
larly considering a mean age of 40.7 years (SD = 11.5)
and a national unemployment rate of 5.6 % in the gen-
eral Brazilian population (according to official national
data) [46]. Similar results were found by other authors
[35, 47]. Furthermore, the majority of patients in all EDSS
levels had been in school for at least 10 years, a similar
result to the one found by Fragoso et al. [48] where pa-
tients have studied for an average of 12.4 years, evidencing
that despite the high schooling levels, a high frequency of
unemployment or early retirement is observed among MS
Brazilian patients.
It was also possible to observe through the health-
related quality of life analysis, expressed as utility mea-
sures, that worsening in disability level led to lower utility
scores – representing a worse assessment by patients of
their own health state. The same results were previously
described by other authors [3, 8, 9, 14–18, 35]. Although
these findings corroborate others previously described, it
is important to note that utility index was calculated using
an algorithm developed for the United Kingdom popula-
tion since an algorithm developed for the Brazilian popu-
lation was not available at the time of data analysis [49].
Some degree of adverse impact of fatigue on daily activ-
ities was perceived by 51 % of the sample, particularly re-
lated to the physical domain. In Brazil, Nogueira et al. [11]
found higher frequencies of self-reported impact of fa-
tigue, about 69 %, using MFIS-BR, and Mendes et al. [12]
also found higher frequencies, 67.4 %, although he used
the Fatigue Severity Scale. Other previous studies also
have shown the association between level of disability and
impact of fatigue, considering different study designs and
sample sizes [3, 50, 51].
Finally, it is important to note that this study protocol
was planned based on methods used on the TRIBUNE
study, conducted on five European countries [35] and
Canada [14]. In all countries where a similar MS study
was conducted, including Brazil, most of the enrolled
da Silva et al. BMC Health Services Research  (2016) 16:102 Page 10 of 12
patients were female, as expected for a disease that af-
fects at least twice as many more women than men [3].
Considering severity level (EDSS), only the United
Kingdom results were similar, with the majority of pa-
tients classified between 4 and 6.5 [35]. In other coun-
tries, considering the combined results for Europe, most
patients were classified in EDSS levels between 0 and 3
[35]. Brazilian data also showed a greater frequency of
severe disability (EDSS 7–9) when compared to other
countries, even with a small number of patients included
in this category.
In relation to the economic impact of MS, study data
corroborated those observed in other countries, showing
that increased healthcare-related costs is directly propor-
tional to increased disability level (if DMT drugs are
considered separately). When only costs with DMTs
were considered, results for all countries are also similar,
showing that costs become inversely proportional to in-
creased disability level [14, 35]. Data on quality of life
also corroborated results from Europe and Canada,
where patients with the most severe disease showed
worst quality of life [14, 35].
Conclusion
This study can make an important contribution to the
existing MS literature in Brazil once it provided a broader
analysis of the economic and psychosocial impacts of MS
on patients, their families and on the Brazilian health sys-
tem. Findings highlighted the considerable economic im-
pact of the disease, both in terms of disease modifying
therapies and other MS management costs. When patients
move upwards on the disease severity scale, costs with
health resources other than DMTs are significantly in-
creased. Worsening disability also had an important influ-
ence on quality of life and self-perceived impact of fatigue
on daily living. Further studies are necessary to assess not
only direct but also indirect costs of MS in Brazil.
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